AC 0137; AC 137; Symlin; Tripro-Amylin; riproamylin; Pramlintide; LS-181996; LS181996; Amylin
Lys-c[Cys-Asn-Thr-Ala-Thr-Cys]-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu -Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly -Ser-Asn-Thr-Tyr-NH2
Long-term Storage Conditions
Pramlintide (Symlin) has been approved by the FDA as a new injectable drug for diabetes (both type 1 and 2).
Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β-cells of the pancreas along with insulin, after a meal. Like insulin, amylin is completely absent in individuals with Type I diabetes.
Areas of Interest